Inspire Medical Systems (INSP) Expected to Announce Earnings on Monday

Inspire Medical Systems (NYSE:INSP - Get Free Report) is projected to post its Q1 2025 quarterly earnings results after the market closes on Monday, May 5th. Analysts expect Inspire Medical Systems to post earnings of ($0.23) per share and revenue of $194.89 million for the quarter.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its quarterly earnings results on Monday, February 10th. The company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. On average, analysts expect Inspire Medical Systems to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Inspire Medical Systems Stock Performance

Shares of INSP traded down $0.20 during midday trading on Thursday, hitting $158.18. The company had a trading volume of 280,820 shares, compared to its average volume of 581,610. The company's 50-day simple moving average is $161.71 and its 200-day simple moving average is $180.41. Inspire Medical Systems has a 1 year low of $123.00 and a 1 year high of $257.40. The firm has a market capitalization of $4.71 billion, a P/E ratio of 91.43, a P/E/G ratio of 2.86 and a beta of 1.39.

Analyst Ratings Changes

Several research firms recently commented on INSP. Robert W. Baird dropped their target price on Inspire Medical Systems from $252.00 to $248.00 and set an "outperform" rating on the stock in a report on Tuesday, February 11th. Truist Financial dropped their price target on shares of Inspire Medical Systems from $250.00 to $235.00 and set a "buy" rating on the stock in a research note on Tuesday, February 11th. Piper Sandler lowered their target price on shares of Inspire Medical Systems from $260.00 to $233.00 and set an "overweight" rating for the company in a report on Monday, February 10th. Stifel Nicolaus decreased their price objective on shares of Inspire Medical Systems from $190.00 to $175.00 and set a "hold" rating for the company in a research note on Monday, April 21st. Finally, Royal Bank of Canada reduced their target price on Inspire Medical Systems from $260.00 to $215.00 and set an "outperform" rating for the company in a report on Tuesday, April 15th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Inspire Medical Systems presently has an average rating of "Moderate Buy" and a consensus price target of $218.90.

Insider Activity

In other news, CTO John Rondoni sold 583 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total transaction of $99,395.67. Following the sale, the chief technology officer now directly owns 10,424 shares in the company, valued at approximately $1,777,187.76. This represents a 5.30 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Randy Ban sold 25,584 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total value of $4,694,664.00. Following the completion of the sale, the insider now owns 7,259 shares in the company, valued at $1,332,026.50. The trade was a 77.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.10% of the company's stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.